Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
CNS Drugs
Published in: CNS Drugs 6/2011

01-06-2011 | Adis Drug Evaluation

Oral Paliperidone

A Review of its Use in the Management of Schizoaffective Disorder

Author: Lily P. H. Yang

Published in: CNS Drugs | Issue 6/2011

Login to get access

Abstract

Oral paliperidone extended or prolonged release (Invega®) is an atypical antipsychotic, and is the first agent approved for the treatment of schizoaffective disorder. Paliperidone (or 9-hydroxyrisperidone) is the major active metabolite of the well known atypical antipsychotic risperidone, and its mechanism of action is thought to be the antagonism of dopamine D2 and serotonin 5-HT2a receptors.
The clinical efficacy of paliperidone was demonstrated in two 6-week, randomized, double-blind, placebo-controlled, multicentre trials in patients with schizoaffective disorder. One trial was flexible dose in design (3–12mg/day) and the other was fixed dose in design (3–6 and 9–12mg/day). Compared with placebo, the change from baseline at study end in the Positive and Negative Syndrome Scale (PANSS) total score (primary endpoint) was significantly greater with paliperidone 3–12mg/day in one trial and with 9–12mg/day (but not 3–6mg/day) in the other trial. However, pooled analyses reported a significantly greater change in PANSS total score across all paliperidone dosages than with placebo.
Paliperidone was generally well tolerated in the 6-week trials, and no unexpected adverse events were reported. The most commonly reported treatment-emergent adverse events were headache, tremor, dizziness, insomnia, nausea, akathisia, dyspepsia, hypertonia, somnolence and sedation.
Although long-term efficacy and tolerability data and comparisons with other antipsychotics are needed, paliperidone appears to be a useful agent for the short-term management of patients with schizoaffective disorder.
Literature
1.
Kantrowitz JT, Citrome L. Schizoaffective disorder: a review of current research themes and pharmacological management. CNS Drugs 2011; 25(4): 317–31PubMedCrossRef
2.
Malhi GS, Green M, Fagiolini A, et al. Schizoaffective disorder: diagnostic issues and future recommendations. Bipolar Disord 2008 Feb; 10(1 Pt 2): 215–30PubMedCrossRef
3.
Laursen TM, Agerbo E, Pedersen CB. Bipolar disorder, schizoaffective disorder, and schizophrenia overlap: a new comorbidity index. J Clin Psychiatry 2009 Oct; 70(10): 1432–8PubMedCrossRef
4.
Cheniaux E, Landeira-Fernandez J, Lessa Telles L, et al. Does schizoaffective disorder really exist? A systematic review of the studies that compared schizoaffective disorder with schizophrenia or mood disorders. J Affect Disord 2008 Mar; 106(3): 209–17PubMedCrossRef
5.
Goff DC, Hill M, Freudenreich O. Strategies for improving treatment adherence in schizophrenia and schizoaffective disorder. J Clin Psychiatry 2010; 71 Suppl. 2: 20–6CrossRef
6.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994
7.
Jäger M, Becker T, Weinmann S, et al. Treatment of schizoaffective disorder: a challenge for evidence-based psychiatry. Acta Psychiatr Scand 2010 Jan; 121(1): 22–32PubMedCrossRef
8.
Gersing K, Burchett B, Turner N, et al. Identifying unique characteristics of schizoaffective disorder [poster]. 21st US Psychiatric and Mental Health Congress; 2009 Nov 2–5; Las Vegas (NV)
9.
Perälä J, Suvisaari J, Saarni SI, et al. Lifetime prevalence of psychotic and bipolar I disorders in a general population. Arch Gen Psychiatry 2007 Jan; 64(1): 19–28PubMedCrossRef
10.
Vieta E. Developing an individualized treatment plan for patients with schizoaffective disorder: from pharmacotherapy to psychoeducation. J Clin Psychiatry 2010; 71 Suppl. 2: 14–9CrossRef
11.
12.
13.
Conley R, Gupta SK, Sathyan G. Clinical spectrum of the osmotic-controlled release oral delivery system (OROS), an advanced oral delivery form. Curr Med Res Opin 2006 Oct; 22(10): 1879–92PubMedCrossRef
14.
Chwieduk CM, Keating GM. Paliperidone extended release: a review of its use in the management of schizophrenia. Drugs 2010; 70(10): 1295–317PubMedCrossRef
15.
Canuso CM, Battisti WP. Paliperidone extended-release: a review of efficacy and tolerability in schizophrenia, schizoaffective disorder and bipolar mania. Expert Opin Pharmacother 2010 Oct; 11(15): 2557–67PubMedCrossRef
16.
Hoy SM, Scott LJ, Keating GM. Intramuscular paliperidone palmitate. CNS Drugs 2010; 24(3): 227–44PubMedCrossRef
17.
Richelson E. New antipsychotic drugs: how do their receptor-binding profiles compare? J Clin Psychiatry 2010 Sep; 71(9): 1243–4PubMedCrossRef
18.
Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci 2000 Nov 24; 68(1): 29–39PubMedCrossRef
19.
Arakawa R, Ito H, Takano A, et al. Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia. Psychopharmacology (Berl) 2008 Apr; 197(2): 229–35CrossRef
20.
Luthringer R, Staner L, Noel N, et al. A double-blind, placebo-controlled, randomized study evaluating the effect of paliperidone extended-release tablets on sleep architecture in patients with schizophrenia. Int Clin Psychopharmacol 2007 Sep; 22(5): 299–308PubMedCrossRef
21.
Schwartzer JJ, Morrison RL, Ricci LA, et al. Paliperidone suppresses the development of the aggressive phenotype in a developmentally sensitive animal model of escalated aggression. Psychopharmacology (Berl) 2009; 203(4): 653–63CrossRef
22.
Corena-McLeaod MdP, Oliveros A, Charlesworth C, et al. Paliperidone as a mood stabilizer: a pre-frontal cortex synaptoneurosomal proteomics comparison with lithium and valproic acid after chronic treatment reveals similarities in protein expression. Brain Res 2008 Oct 3; 1233: 8–19CrossRef
23.
Schmidt AJ, Krieg JC, Clement HW, et al. Effects of quetiapine, risperidone, 9-hydroxyrisperidone and ziprasidone on the survival of human neuronal and immune cells in vitro. J Psychopharmacol 2010 Mar; 24(3): 349–54PubMedCrossRef
24.
Zhu HJ, Wang JS, Markowitz JS, et al. Risperidone and paliperidone inhibit P-glycoprotein activity in vitro. Neuropsychopharmacology 2007 Apr; 32(4): 757–64PubMedCrossRef
25.
Boom S, Talluri K, Janssens L, et al. Single- and multiple-dosepharmacokinetics and dose proportionality of the psychotropic agent paliperidone extended release. J Clin Pharmacol 2009 Nov; 49(11): 1318–30PubMedCrossRef
26.
Vermeir M, Naessens I, Remmerie B, et al. Absorption, metabolism, and excretion of paliperidone, a new mono-aminergic antagonist, in humans. Drug Metab Dispos 2008 Apr; 34(4): 769–79CrossRef
27.
Thyssen A, Cleton A, van Osselaer N, et al. Effects of renal impairment on the pharmacokinetic profile of paliperidone extended-release tablets [poster]. 3rd Pharmaceutical Sciences World Congress; 2007 Apr 22–25; Amsterdam
28.
Boom S, Thyssen A, Crauwels H, et al. The influence of hepatic impairment on the pharmacokinetics of paliperidone. Int J Clin Pharmacol Ther 2009 Oct; 47(10): 606–16PubMed
29.
Cleton A, Rossenu S, Boom S, et al. Evaluation of the pharmacokinetics of paliperidone extended-release tablets in healthy elderly subjects [poster]. 3rd Pharmaceutical Sciences World Congress; 2007 Apr 22–25; Amsterdam
30.
Berwaerts J, Cleton A, Herben V, et al. The effects of paroxetine on the pharmacokinetics of paliperidone extended-release tablets. Pharmacopsychiatry 2009 Jul; 42(4): 158–63PubMedCrossRef
31.
Thyssen A, Cleton A, Talluri K, et al. No pharmacokineticinteraction between paliperidone extended-release tablets and trimethoprim in healthy subjects. Hum Psychopharmacol 2009 Oct; 24(7): 532–9PubMedCrossRef
32.
Canuso CM, Schooler N, Carothers J, et al. Paliperidone extended-release in schizoaffective disorder: a randomized, controlled study comparing a flexible dose with placebo in patients treated with and without antidepressants and/or mood stabilizers. J Clin Psychopharmacol 2010 Oct; 30(5): 487–95PubMedCrossRef
33.
Canuso CM, Lindenmayer JP, Kosik-Gonzalez C, et al. A randomized, double-blind, placebo-controlled study of 2 dose ranges of paliperidone extended-release in the treatment of subjects with schizoaffective disorder. J Clin Psychiatry 2010 May; 71(5): 587–98PubMedCrossRef
34.
Canuso CM, Turkoz I, Fu DJ, et al. Role of paliperidone extended-release in treatment of schizoaffective disorder. Neuropsychiatr Dis Treat 2010 Oct; 6: 667–79PubMedCrossRef
35.
Meltzer HY, Bobo WV, Nuamah IF, et al. Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies. J Clin Psychiatry 2008; 69(5): 817–29PubMedCrossRef
36.
Emsley R, Berwaerts J, Eerdekens M, et al. Efficacy and safety of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 52-week open-label studies. Int Clin Psychopharmacol 2008 Nov; 23(6): 343–56PubMedCrossRef
37.
Harrington CA, English C. Tolerability of paliperidone: a meta-analysis of randomized, controlled trials. Int Clin Psychopharmacol 2010 Nov; 25(6): 334–41PubMedCrossRef
38.
Trollor JN, Chen X, Sachdev PS. Neuroleptic malignant syndrome associated with atypical antipsychotic drugs. CNS Drugs 2009; 23(6): 477–92PubMedCrossRef
39.
Kramer M, Simpson G, Maciulis V, et al. Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 2007 Feb; 27(1): 6–14PubMedCrossRef
40.
Duggal HS. Possible neuroleptic malignant syndrome associated with paliperidone [letter]. J Neuropsychiatry Clin Neurosci 2007 Fall; 19(4): 477–8PubMedCrossRef
41.
Mantas C, Kalabokis G, Goulia P, et al. Possible neuroleptic malignant syndrome during paliperidone administration: a case report [letter]. J Clin Psychopharmacol 2010 Feb; 30(1): 89–91PubMedCrossRef
42.
Han C, Lee SJ, Pae CU. Paliperidone-associated atypical neuroleptic malignant syndrome: a case report [letter]. Prog Neuropsychopharmacol Biol Psychiatry 2011 Mar; 35(2): 650–1PubMedCrossRef
43.
Nayak RB, Bhogale GS, Patil NM, et al. Paliperidone-induced neuroleptic malignant syndrome [letter]. J Neuropsychiatry Clin Neurosci 2011 Fall; 23(1): E14–5PubMedCrossRef
44.
Hough DW, Natarajan J, Vandebosch A, et al. Evaluation of the effect of paliperidone extended release and quetiapine on corrected QT intervals: a randomized, double-blind, placebo-controlled study. Int Clin Psychopharmacol 2011 Jan; 26(1): 25–34PubMedCrossRef
45.
Schreiner A, Tessier C, Hoeben D, et al. A prospective randomized controlled trial of paliperidone ER versus oral olanzapine in patients with schizophrenia [poster]. 18th European Congress of Psychiatry; 2010 Feb 27–Mar 2; Munich
46.
Olfson M, Marcus SC, Wan GJ. Treatment patterns for schizoaffective disorder and schizophrenia among Medicaid patients. Psychiatr Serv 2009 Feb; 60(2): 210–6PubMedCrossRef
47.
Malhi GS, Berk M, Bourin M, et al. Atypical mood stabilizers: a ‘typical’ role for atypical antipsychotics. Acta Psychiatr Scand Suppl 2005; 111 Suppl. 426: 29–38PubMedCrossRef
48.
Potkin SG, Saha AR, Kujawa MJ, et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003 Jul; 60(7): 681–90PubMedCrossRef
49.
Keck Jr PE, Reeves KR, Harrigan EP, et al. Ziprasidone inthe short-term treatment of patients with schizoaffective disorder: results from two double-blind, placebo-controlled, multicenter studies. J Clin Psychopharmacol 2001 Feb; 21(1): 27–35PubMedCrossRef
50.
Glick ID, Mankoski R, Eudicone JM, et al. The efficacy, safety, and tolerability of aripiprazole for the treatment of schizoaffective disorder: results from a pooled analysis of a sub-population of subjects from two randomized, double-blind, placebo-controlled, pivotal trials. J Affect Disord 2009 May; 115(1–2): 18–26PubMedCrossRef
51.
Janicak PG, Keck Jr PE, Davis JM, et al. A double-blind, randomized, prospective evaluation of the efficacy and safety of risperidone versus haloperidol in the treatment of schizoaffective disorder. J Clin Psychopharmacol 2001 Aug; 21(4): 360–8PubMedCrossRef
52.
Sajatovic M, Mullen JA, Sweitzer DE. Effiacy of quetiapine and risperidone against depressive symptoms in outpatients with psychosis. J Clin Psychiatry 2002 Dec; 63(12): 1156–63PubMedCrossRef
53.
Leucht S, Kane JM, Etschel E, et al. Linking the PANSS, BPRS, and CGI: clinical implications. Neuropsycho-pharmacology 2006 Oct; 31(10): 2318–25
54.
Regenold WT, Thapar RK, Marano C, et al. Increased prevalence of type 2 diabetes mellitus among psychiatric inpatients with bipolar I affective and schizoaffective disorders independent of psychotropic drug use. J Affect Disord 2002 Jun; 70(1): 19–26PubMedCrossRef
55.
Kilbourne AM, Brar JS, Drayer RA, et al. Cardiovascular disease and metabolic risk factors in male patients with schizophrenia, schizoaffective disorder, and bipolar disorder. Psychosomatics 2007 Sep–Oct; 48(5): 412–7PubMedCrossRef
56.
van Winkel R, van Os J, Celic I, et al. Psychiatric diagnosis as an independent risk factor for metabolic disturbances: results from a comprehensive, naturalistic screening program. J Clin Psychiatry 2008 Aug; 69(8): 1319–27PubMedCrossRef
57.
American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, et al. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004 Feb; 27(2): 596–601CrossRef
58.
Nasrallah HA. Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry 2008 Jan; 13(1): 27–35PubMedCrossRef
59.
Álvarez-Jiménez M, González-Blanch C, Crespo-Facorro B, et al. Antipsychotic-induced weight gain in chronic and first-episode psychotic disorders: a systematic critical reappraisal. CNS Drugs 2008; 22(7): 547–62PubMedCrossRef
60.
Sheehan JJ, Sliwa JK, Amatniek JC, et al. Atypical antipsychotic metabolism and excretion. Curr Drug Metab 2010 Jul; 11(6): 516–25PubMedCrossRef
61.
Ortho-McNeil Janssen Scientific Affairs, LLC. A study to evaluate the efficacy of paliperidone palmitate in the prevention of relapse of the symptoms of schizoaffective disorder [ClinicalTrials.gov identifier NCT01193153]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://​www.​clinicaltrials.​gov [Accessed 2011 May 9]
62.
63.
Metadata
Title
Oral Paliperidone
A Review of its Use in the Management of Schizoaffective Disorder
Author
Lily P. H. Yang
Publication date
01-06-2011
Publisher
Springer International Publishing
Published in
CNS Drugs / Issue 6/2011
Print ISSN: 1172-7047
Electronic ISSN: 1179-1934
DOI
https://doi.org/10.2165/11207440-000000000-00000

Other articles of this Issue 6/2011

CNS Drugs 6/2011 Go to the issue

Leading Article

Suicidal Ideation during Antidepressant Treatment

Adis Drug Profile

Fentanyl Pectin Nasal Spray

Review Article

Assessing QT Interval Prolongation and its Associated Risks with Antipsychotics

Current Opinion

Pharmacotherapy for Primary CNS Lymphoma

Review Article

The Mechanism of Action of Interferon-β in Relapsing Multiple Sclerosis

Short Communication

Lower IQ is Associated with Decreased Clinical Response to Atomoxetine in Children and Adolescents with Attention-Deficit Hyperactivity Disorder